Inhibition of colorectal cancer progression through conformation-specific targeting of ADAM10 metalloprotease
Frontiers in Oncology · 27.01.2026 · 15
DOI: 10.3389/fonc.2025.1704436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 27.01.2026. Verfasst von Pargol Mashati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Current first- and second-line therapies rely on oxaliplatin- or irinotecan-based combination chemotherapies combined with antibody-mediated inhibition of EGFR- or VEGF-dependent signaling, but these regimens are associated with significant side effects that limit long-term use and effectiveness. ADAM10 has emerged as a potential therapeutic target in CRC due to its role in activating oncogenic pathways such as Notch and EGFR; however, prior approaches targeting ADAM10 showed high toxicity. ADAM10 exists in an open, active conformation and a closed, auto-inhibited conformation, with the active form being more prevalent in tumor cells, providing a rationale for conformation-specific targeting.
Methods
To investigate the therapeutic potential of 1H5, cellular viability was assessed using viability assays, and ADAM10 dependency was evaluated by shRNA-mediated knockdown. Modulation of oncogenic signaling pathways and target gene expression was validated by Western blotting and RT-qPCR, while transcriptomic changes were analyzed by bulk RNA sequencing. The effects of 1H5 on cell migration and invasion were assessed using wound-healing and transwell invasion assays, and therapeutic efficacy was evaluated in vivo using xenograft and syngeneic mouse models.
Results
We show that 1H5 inhibits Notch and EGFR signaling and reduces proliferation of human CRC cell lines. We also found that 1H5 inhibits Wnt/β-catenin signaling in CRC cells and reduces their migration and invasion capacity. Finally, treatment studies in CRC cell line-derived xenograft models revealed marked antitumorigenic properties of 1H5.
Discussion
Together, these findings demonstrate that selective targeting of the active conformation of ADAM10 enables simultaneous inhibition of multiple oncogenic pathways involved in CRC growth and progression and represents a promising therapeutic strategy warranting further clinical evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, United States.
- Mirimus, Inc., Brooklyn, NY, United States.
- Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Mashati, P., Sun, D., Reino, E. G., Militello, G., Gao, N., Blandino, J. A., Saha, N., Nikolov, D. B., & Premsrirut, P. K. (2026). Inhibition of colorectal cancer progression through conformation-specific targeting of ADAM10 metalloprotease. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1704436
Vancouver
Mashati P, Sun D, Reino EG, Militello G, Gao N, Blandino JA, et al. Inhibition of colorectal cancer progression through conformation-specific targeting of ADAM10 metalloprotease. Frontiers in Oncology. 2026;15. doi:10.3389/fonc.2025.1704436
BibTeX
@article{Mashati2026,
author = {Mashati, Pargol and Sun, Dan and Reino, Eduardo Garcia and Militello, Giuseppe and Gao, Nicholas and Blandino, Jessica A and Saha, Nayanendu and Nikolov, Dimitar B and Premsrirut, Prem K},
title = {Inhibition of colorectal cancer progression through conformation-specific targeting of ADAM10 metalloprotease},
journal = {Frontiers in Oncology},
year = {2026},
volume = {15},
doi = {10.3389/fonc.2025.1704436}
}
EUVIMED